Neurovascular Devices Market Size, Share, Trends, Growth and Forecast 2026–2034

Neurovascular Devices Market Overview By Fortune Business Insights Analysis

Market Size & Growth Outlook

According to Fortune Business Insights: The global neurovascular devices market was valued at USD 4.08 billion in 2025 and is projected to grow from USD 4.46 billion in 2026 to USD 9.82 billion by 2034, exhibiting a CAGR of 10.40% during the forecast period. North America dominated the market with a 43.60% share in 2025, generating USD 1.78 billion in revenue — driven by high neurovascular disease prevalence, superior diagnosis and treatment rates, favorable reimbursement policies, and the presence of leading global device manufacturers.

Neurovascular devices are specialized medical instruments used in the interventional treatment of neurovascular disorders — including brain aneurysms, ischemic stroke, arteriovenous malformations, and related cerebrovascular conditions. The device category encompasses stenting systems, embolization devices, neurothrombectomy devices, and support devices — all deployed through minimally invasive endovascular procedures. The accelerating global burden of neurovascular diseases combined with the increasing development of technologically advanced interventional devices is sustaining strong market growth globally.

Get a Sample Research PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/101684

Market Trends

Increasing R&D Investment and Advanced Technology Adoption Elevating Device Performance: The defining trend reshaping the global neurovascular devices market is the sustained commitment of leading players to research and development — focusing on underpenetrated areas of neurovascular intervention and continuously introducing next-generation devices with improved clinical efficacy and safety. Development of advanced embolic coils, aspiration catheters, flow diverters, and revascularization devices for ischemic stroke treatment represents the leading wave of innovation transforming the market. Penumbra, Inc. is conducting the CHEETAH clinical trial for its Indigo System CAT RX Aspiration Catheter — which achieved its primary endpoint in clot retrieval in November 2021. NeuroVasc Technologies announced the first patient treated in its clinical trial evaluating the NeuroVasc Envi-SR novel stent-retriever for ischemic stroke treatment in June 2022. In February 2024, Route 92 Medical completed enrollment for its HiPoint Reperfusion Catheters in the SUMMIT MAX clinical trial — collectively illustrating the pipeline depth fueling market advancement.

Market Drivers

Rising Incidence of Neurovascular Conditions Sustaining Structural Demand: The primary growth driver is the escalating global burden of neurovascular diseases — particularly stroke and cerebral aneurysms — which is generating a large and growing patient population requiring interventional treatment. According to WHO data published in 2022, the global risk of stroke increased by 50% over the preceding 17 years, with 1 in 4 individuals expected to suffer a stroke during their lifetime. The CDC reported approximately 800,000 people suffer a stroke annually in the U.S. — more than 75% occurring in adults aged 65 years and above. The Brain Aneurysm Foundation estimated that approximately 15.0 million people suffer strokes globally every year, with around 6.7 million people carrying an unruptured brain aneurysm — and approximately 30,000 ruptures occurring in the U.S. annually. According to a study published by Elsevier B.V. in 2023, the prevalence of stroke in the elderly population was approximately 7.4% globally. The rising geriatric population, combined with sedentary lifestyles and increasing hypertension prevalence, is sustaining this elevated patient burden — directly driving device procurement across hospitals and specialty clinics globally.

Government Initiatives Expanding Diagnosis and Treatment Awareness: Growing recognition of neurovascular conditions as critical public health priorities has prompted governments and international health organizations to implement structured national stroke action plans and neurological disorder management frameworks. In May 2021, the Ukrainian Ministry of Health signed the Stroke Action Plan for Europe in coordination with the European Stroke Organization — complementing the national stroke plan it launched in 2019 to drive technical excellence and expand investment in stroke care infrastructure. Such coordinated policy actions expand the diagnosed and treated patient pool — supporting sustained device adoption growth across both established and emerging healthcare systems.

Market Restraint

Delayed Diagnosis and Misdiagnosis Limiting Patient Access to Treatment: The primary market restraint is the significant rate of delayed diagnosis and misdiagnosis of neurovascular conditions — particularly brain aneurysms — which reduces the patient population accessing timely interventional treatment. According to the Brain Aneurysm Foundation in 2022, approximately one in every four patients with brain aneurysms in the U.S. receives a misdiagnosis or experiences delayed diagnosis — primarily due to failure to perform brain imaging in emergency settings and insufficient physician expertise in neurological assessment. In developing countries including India and China, the delayed diagnosis rate is considerably higher — compounded by limited awareness among the general population, inadequate healthcare infrastructure, and the absence of established clinical guidelines — collectively constraining market penetration in regions with the highest growth potential.

Segmentation Analysis

By Device Type: Embolization devices dominate with a projected 45.29% market share in 2026, driven by the high global volume of patients receiving treatment for cerebral aneurysms — for which embolization is a clinically proven first-line procedure — alongside increasing new product launches, including Penumbra's POD Embolization Anchoring Device. The neurothrombectomy devices segment is expected to register a significant CAGR during the forecast period, driven by the rising prevalence of acute ischemic stroke and the growing volume of product launches by key players. In April 2019, Medtronic launched the Solitaire X Revascularization Device in the U.S. — specifically designed to remove blood clots in the brain. In June 2022, MicroPort Scientific Corporation completed the first commercial U.S. implantation of its Numen Coil Embolization System. Stenting systems are growing steadily, supported by rising preference for minimally invasive neurological procedures across hospitals and specialty clinics.

By Application: Cerebral aneurysms dominated the market in 2024, driven by the high global prevalence of the condition and the availability of clinically validated embolization and coiling devices for its treatment. The ischemic stroke segment is expected to grow at the highest application CAGR — reflecting the condition's overwhelming prevalence, with the CDC reporting ischemic stroke representing approximately 87% of all stroke types in 2020. Market players are actively targeting this segment with advanced mechanical thrombectomy and aspiration catheter technologies to address the large unmet treatment need.

By End-User: Hospitals dominate with a projected 72.20% market share in 2026 — reflecting their role as the primary care environment for neurovascular interventional procedures, higher adoption of cutting-edge endovascular technologies, and their status as leading causes of inpatient admissions for neurovascular conditions across the U.S., U.K., and other countries during 2014–2019 per national hospital databases. Specialty clinics are expected to grow at a significant CAGR during the forecast period, driven by the increasing number of specialty neurovascular centers in developed countries and improving interventional neurology infrastructure in emerging markets including China, India, and Brazil.

Regional Outlook

North America leads the global market at USD 1.78 billion in 2025 (43.60% share), projected to reach USD 1.96 billion in 2026. The U.S. market — projected to reach USD 1.88 billion by 2026 — benefits from the highest neurovascular disease diagnosis and treatment rates globally, adequate reimbursement for neurovascular procedures including all embolic and liquid coils through Medicare, Medicaid, and private insurers, and a highly advanced device innovation ecosystem. In December 2022, Stryker launched a state-of-the-art Neurovascular R&D lab designed to accelerate stroke care innovation, further strengthening North America's leadership in neurovascular device development.

Europe held USD 1.06 billion in 2025 (26.00% share), projected to reach USD 1.16 billion in 2026. Growth is driven by rising product launches for neurovascular disease treatment, increasing focus on proper neurological condition management, and new regulatory approvals expanding device access. Germany leads the region at a projected USD 0.35 billion by 2026, while the U.K. follows at USD 0.16 billion. In April 2019, Medtronic received extended approval for its Pipeline Flex embolization device across European markets for adult cerebral aneurysm treatment.

Asia Pacific generated USD 0.96 billion in 2025 (23.60% share), projected to reach USD 1.05 billion in 2026. Growing strategic initiatives by key players to expand device penetration, rising treatment awareness among patient populations, and improving healthcare infrastructure are driving regional market growth. India leads the region at a projected USD 0.85 billion by 2026, while Japan follows at USD 0.53 billion and China at USD 0.22 billion. In January 2021, Genesis Medtech collaborated with Penumbra, Inc. to expand neurovascular device market penetration across China.

Latin America generated USD 0.17 billion in 2025 (4.30% share), projected to reach USD 0.19 billion in 2026, with growing disease awareness and improving healthcare infrastructure driving adoption. In August 2022, Wallaby Medical launched its pRESET thrombectomy device in Brazil — illustrating the region's growing market access for advanced neurovascular solutions.

Middle East & Africa reached USD 0.10 billion in 2025 (2.50% share), projected to reach USD 0.11 billion in 2026, supported by developing healthcare infrastructure and growing neurological disease awareness in the GCC and South Africa.

Connect with Our Expert for any Queries: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/101684

Competitive Landscape

The global neurovascular devices market is consolidated, led by Stryker (U.S.), Medtronic (U.S.), Penumbra Inc. (U.S.), Johnson & Johnson/CERENOVUS (U.S.), MicroVention Inc. (U.S.), MicroPort Scientific Corporation (China), Terumo Corporation (Japan), ASAHI INTECC CO. LTD. (Japan), NeuroVasc Technologies Inc. (U.S.), Acandis GmbH (Germany), and Perflow Medical Ltd. (Israel). Competition centers on pipeline depth, clinical evidence generation, regulatory approvals, and geographic expansion through strategic partnerships.

Key recent developments include Penumbra's January 2023 FDA-approved launch of the Lightning Flash mechanical thrombectomy system; iVascular's November 2022 launch of CE-marked iNdeep microcatheter, iNtercept retriever, and iNedit and iNstroke aspiration catheters; Medtronic's October 2022 launch of its Neurovascular Co-Lab Platform to accelerate stroke care innovation; Penumbra's September 2022 RED reperfusion catheter launch in Europe; and MicroPort Scientific Corporation's June 2022 first commercial U.S. implantation of the Numen Coil Embolization System.

Uncover Japan’s Market Trends - Explore the Latest - Neurovascular Devices Market Insights